Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Diphenhydramine HCL Clear all
Completed Phase 3 Interventional Results available

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

NCT00474786
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Sorafenib, temsirolimus (Torisel)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
26
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

NCT04375384
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
Interventions
Cetuximab, Questionnaire administration, Quality of life assessment
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

NCT01248962
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Effects of Intravenous Lidocaine on Endometriosis Pain

NCT01968694
View directory record Official record
Conditions
Endometriosis
Interventions
IV Lidocaine, IV diphenhydramine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional

T-Cell Therapy for Advanced Breast Cancer

NCT02792114
View directory record Official record
Conditions
Breast Cancer, Metastatic HER2-negative Breast
Interventions
Cyclophosphamide, Mesothelin-targeted T cells, AP1903
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02272790
View directory record Official record
Conditions
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions
Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
18
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

NCT02023164
View directory record Official record
Conditions
Acute Urticaria
Interventions
JDP-205 Injection, Diphenhydramine
Drug
Lead sponsor
JDP Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 4 Interventional Results available

Post-Operative Therapy for Nausea or Vomiting

NCT03075163
View directory record Official record
Conditions
Vomiting, Nausea
Interventions
Acupressure, Ondansetron
Procedure · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

NCT00576758
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
obinutuzumab (RO5072759), rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Transplantation in Crohn's Disease

NCT04224558
View directory record Official record
Conditions
Crohn Disease
Interventions
Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
Drug · Procedure · Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years to 28 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

NCT01264939
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Withdrawn Not applicable Interventional

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

NCT00657228
View directory record Official record
Conditions
Anaphylaxis
Interventions
Intravenous heparin, Saline
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Trial of Naproxen Sodium/ Diphenhydramine

NCT01365052
View directory record Official record
Conditions
Pain
Interventions
Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Peoria, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

NCT02552394
View directory record Official record
Conditions
Prostate Cancer
Interventions
huJ591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.

NCT07778472
View directory record Official record
Conditions
Healthy
Interventions
Tripelennamine, Diphenhydramine, Vehicle Control Cream Base
Drug
Lead sponsor
Palm Beach Atlantic University
Other
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

NCT04580121
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Therapies for Down Syndrome Regression Disorder

NCT05662228
View directory record Official record
Conditions
Down Syndrome, Regression
Interventions
Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Not applicable Interventional

Chicago Social Drinking Project

NCT00961792
View directory record Official record
Conditions
Alcoholism
Interventions
Ethanol, Placebo, Diphenhydramine, Caffeine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

NCT01810588
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
Device · Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 4 Interventional

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

NCT00648973
View directory record Official record
Conditions
Nasal Congestion
Interventions
Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 28, 2026, 9:03 PM EDT
Withdrawn Early Phase 1 Interventional

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Drug · Device
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 28, 2026, 9:03 PM EDT